Amphastar Pharmaceuticals
- Country
- 🇺🇸United States
- Ownership
- Public
- Established
- 1996-01-01
- Employees
- 1.7K
- Market Cap
- $2.3B
- Website
- http://www.amphastar.com
- Introduction
Amphastar Pharmaceuticals, Inc. engages in developing, manufacturing, marketing, and selling technically challenging generic and proprietary injectable, inhalation, and intranasal products, and insulin active pharmaceutical ingredient. It operates through Finished Pharmaceutical Products and Active Pharmaceutical Ingredients Products segments. The Finished Pharmaceutical Products segment manufactures, markets, and distributes Primatene Mist, enoxaparin, naloxone, phytonadione, lidocaine, and other critical and non-critical care drugs. The Active Pharmaceutical Ingredients Products segment offers RHI API and porcine insulin API for external customers and internal product development. The company was founded by Zi-Ping Luo and Yong Feng Zhang on February 29, 1996 and is headquartered in Rancho Cucamonga, CA.
Epinephrine Inhalation Aerosol USP: For Evaluation Of Efficacy And Safety In Asthma Patients
- First Posted Date
- 2011-05-23
- Last Posted Date
- 2016-03-11
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 373
- Registration Number
- NCT01357642
- Locations
- 🇺🇸
West Coast Clinical Trials, Costa Mesa, California, United States
🇺🇸Southern California Institute for Respiratory Diseases, Los Angeles, California, United States
🇺🇸Asthma and Allergy Associates of Southern California, Mission Viejo, California, United States
Epinephrine Inhalation Aerosol USP, CLINICAL STUDY-B3 FOR ASSESSMENT OF PHARMACOKINETICS
- Conditions
- Asthma
- First Posted Date
- 2010-12-07
- Last Posted Date
- 2016-03-17
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01255709
- Locations
- 🇺🇸
Amphastar Study Site 1, Cypress, California, United States
Escalating and Cumulative-Dose Study of Pharmacokinetics (PK), Pharmacodynamics (PD) and Safety of A006
- Conditions
- AsthmaBronchospasmChronic Obstructive Pulmonary Disease (COPD)
- Interventions
- First Posted Date
- 2010-08-26
- Last Posted Date
- 2017-07-02
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 27
- Registration Number
- NCT01189396
- Locations
- 🇺🇸
Amphastar Site 0026, Portland, Oregon, United States
🇺🇸Amphastar Site 0025, Medford, Oregon, United States
🇺🇸Amphastar Site 0032, San Antonio, Texas, United States
Epinephrine Inhalation Aerosol USP, a HFA-MDI Study for Assessment of Pharmacokinetics
- Conditions
- AsthmaBronchospasmWheezingShortness of Breath
- Interventions
- First Posted Date
- 2010-08-25
- Last Posted Date
- 2017-07-25
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 23
- Registration Number
- NCT01188577
- Locations
- 🇺🇸
Amphastar Site 0035, Cypress, California, United States
Dose-Ranging Study of A006 DPI, in Adult Asthma Patients
- Conditions
- BronchospasmAsthma
- Interventions
- First Posted Date
- 2010-08-04
- Last Posted Date
- 2017-04-19
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 26
- Registration Number
- NCT01174732
- Locations
- 🇺🇸
Amphastar Site 0039, Lakewood, Colorado, United States
🇺🇸Amphastar Site 0001, San Jose, California, United States
🇺🇸Amphastar Site 0008, Denver, Colorado, United States
Pharmacokinetics (PK) Study of Epinephrine Inhalation Aerosol in Healthy Volunteers
- First Posted Date
- 2010-06-14
- Last Posted Date
- 2018-09-25
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT01143051
- Locations
- 🇺🇸
Amphastar Location 1, Cypress, California, United States
Randomized, Placebo/Active Crossover Dose-ranging Study for Safety and Efficacy in Asthma Patients.
- Conditions
- Asthma
- Interventions
- Drug: E004 (epinephrine inhalation aerosol), 220 mcgDrug: E004 (epinephrine inhalation aerosol), 90 mcg/actuationDrug: E004 (epinephrine inhalation aerosol), 125 mcgDrug: E004 (epinephrine inhalation aerosol), 160 mcgDrug: E004 Placebo
- First Posted Date
- 2009-12-03
- Last Posted Date
- 2018-05-16
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 9
- Registration Number
- NCT01025648
- Locations
- 🇺🇸
Amphastar Site 0003, Stockton, California, United States
🇺🇸Amphastar Site 0001, San Jose, California, United States
Single-Dose Cross-Over Study of the Effects of Albuterol-HFA in Exercise Induced Bronchoconstriction
- Conditions
- AsthmaBronchospasm
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 24
- Registration Number
- NCT00634829
- Locations
- 🇺🇸
Colorado Allergy and Asthma Center, Lakewood, Colorado, United States
Controlled, 12-Week Study of Albuterol HFA Versus the Active Control, Proventil(R)-HFA in Asthmatic Patients
- Conditions
- Asthma
- Interventions
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 300
- Registration Number
- NCT00635505
- Locations
- 🇺🇸
Pulmonary Associates of Mobile, PC, Mobile, Alabama, United States
🇺🇸MEDEX Healthcare Research, Inc., St. Louis, Missouri, United States
🇺🇸The Clinical Research Center, LLC, St. Louis, Missouri, United States
4-Week Study of Efficacy, Safety and PK of Albuterol-HFA Versus Proventil-HFA in Pediatric Asthma
- Conditions
- Asthma
- Interventions
- Drug: Armstrong Albuterol Sulfate Inhalation Aerosol
- First Posted Date
- 2008-03-13
- Last Posted Date
- 2013-07-15
- Lead Sponsor
- Amphastar Pharmaceuticals, Inc.
- Target Recruit Count
- 48
- Registration Number
- NCT00634517
- Locations
- 🇺🇸
Integrated Medical Research, Ashland, Oregon, United States
🇺🇸Allergy Associates Research Center, Portland, Oregon, United States
🇺🇸Allergy Associates Medical Group, Inc., San Diego, California, United States